Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have earned an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $13.50.
A number of research analysts recently weighed in on ALLO shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Tuesday, March 19th. Finally, JPMorgan Chase & Co. decreased their price objective on Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 27th.
Check Out Our Latest Report on Allogene Therapeutics
Institutional Investors Weigh In On Allogene Therapeutics
Allogene Therapeutics Price Performance
Allogene Therapeutics stock opened at $2.86 on Tuesday. The stock has a market capitalization of $488.26 million, a PE ratio of -1.37 and a beta of 0.90. The business has a 50 day simple moving average of $3.99 and a 200-day simple moving average of $3.53. Allogene Therapeutics has a 12 month low of $2.23 and a 12 month high of $6.89.
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.04. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Allogene Therapeutics had a negative net margin of 202,366.25% and a negative return on equity of 53.76%. On average, equities research analysts anticipate that Allogene Therapeutics will post -1.69 EPS for the current fiscal year.
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Featured Articles
- Five stocks we like better than Allogene Therapeutics
- How to Invest in Insurance Companies: A GuideĀ
- Roblox: The Bottom Just Fell Out of the Metaverse
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.